Drug Profile
XED 60
Alternative Names: XED-60Latest Information Update: 27 Aug 2019
Price :
$50
*
At a glance
- Originator Lion Corporation
- Class Eye disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Dry eyes
Most Recent Events
- 27 Aug 2019 No development reported - Phase-II for Dry eyes in Japan (Ophthalmic)
- 30 Nov 2015 Lion Corporation completes a phase II trial in Dry eye in Japan before March 2016 (Ophthalmic) (JapicCTI-152829)
- 11 Mar 2015 Phase-II clinical trials in Dry eyes in Japan (Ophthalmic) (JapicCTI-152829)